ABSTRACT:
Since the identification of gastro erosive reflux disease and peptic ulcer in the early 1900’s, the line of treatment of the disease has evolved reasonably. The antisecretory agents used in the treatment regime have developed, beginning with the introduction of cimetidine in the mid-1970s to proton pump inhibitor (PPI) omeprazole in 1989 and subsequently dexlansoprazole dual delayed release in 2009. This development was done to address the unmet needs of patients suffering from severe esophagitis and nocturnal acid breakthrough (NAB). The available PPI formulations which had short plasma elimination half life of less than 2 hours could not inhibit the proton pumps synthesized in the nighttime hours. The inadequacy in symptom control and high prevalence of NAB in patients with more severe gastro esophageal disease still prevailed after medication. This was identified as the unmet needs of PPI formulations. Although novel formulations, including immediate release omeprazole may offer some advantages over existing formulations, it does not address many of the potential unmet needs of patients with these disorders. However, these needs are addressed by dual delayed release technology which delivers dose in a pulsatile manner and provides acid suppression for prolonged period of time.
Cite this article:
Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 5(1): Jan. 2012; Page 20-26,
Cite(Electronic):
Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 5(1): Jan. 2012; Page 20-26, Available on: https://rjptonline.org/AbstractView.aspx?PID=2012-5-1-30
REFERENCES:
1. Dent J.
Review article: from 1906 to 2006- a century of major evolution of
understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther.
2006; 24: 1269-81
2. Tanimura,T.et al. Prevalence of gastro-oesophageal
reflux disease in patients who attended the emergency room. Nippon Shokakibyo
Gakki Zasshi. 2008; 105, 54-59
3. Kahrilas
P.J, Shaheen N.J, Vaezi M.F, American Gastroenterological Association
Institute, Clinical Practice and Quality Management Committee. American
Gastroenterological Association Institute technical review on management of
gastrooesophageal reflux disease. Gastroenterology. 2008; 135(4): 1392-1413
4. Mainie
I, Tutuian R, Shay S. et al. Acid and
non-acid reflux in patients with persistent symptoms despite acid suppressive
therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
Gut. 2006; 55(10): 1398-1402
5. Vakil
N, Van Zanten S.V, Kahrilas P, Dent J, Jones R. The Montreal definition and
classification of Gastro-esophageal Reflux Disease (GERD) – a global evidence
based consensus. Am J Gastroenterol. 2006; 101: 1900-20
6. Katz
P.O, Scheiman J.M, Barkun A.N. Review article: acid-related disease – what are
the unmet clinical needs? Aliment Pharmacol Ther. 2006; 23: 9–22
7. Heresey
S.J, Sachs G, Gastric acid secretion. Physiol Rev. 1995; 75: 155-89
8. Fass R.
Nocturnal Acid Breakthrough: A Critical Assessment. Hospital Physican. 2004;
47-52
9. Fass R,
Chey W.D, Zakko S.F. et al. Clinical
trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime
and nighttime heartburn in patients with non-erosive reflux disease. Aliment
Pharmacol Ther. 2009; 29: 1261-72
10. Sachs
G, Shin J.M, Howden C.W. Review article: the clinical pharmacology of proton
pump inhibitors. Aliment Pharmacol Ther.2006; 23: 2–8
11. Stedman
C.A.M, Barclay M.L. Review article: comparison of the pharmacokinetics, acid
suppression and efficacy of proton pump inhibitor. Aliment Pharmacol Ther.
2000; 14: 963-78
12. Keith
M.O, Margret L.H. Dexlansoprazole MR in the Management of Gastroesophageal
Reflux Disease. Clinical Medicine:Ther. 2009; 1: 1641-52
13. Collin
Jones D.G. The role and limitations of H2-receptor antagonists in
the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther.
1995; 9(1): 9-14
14.
Wilder-Smith C.H, Merki H.S. Tolerance
during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol.
1992; 27(Suppl. 193):14–9.
15.
Lachman L, Howden C.W. Twenty-four-hour
intragastric pH: tolerance within 5 days of continuous ranitidine
administration. Am J Gastroenterol. 2000; 95: 57–61.
16.
Fackler W.K, Ours T.M, Vaezi M.F, Richter
J.E. Long-term effect of H2RA therapy on nocturnal gastric acid
breakthrough. Gastroenterology. 2002; 122: 625–32.
17.
Peghini P.L, Katz P.O, Bracy N.A, Castell
D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of
proton pump inhibitors. Am J Gastroenterol. 1998; 9: 763–67.
18.
Xue S, Katz PO, Banerjee P, Tutuian R,
Castell DO. BedtimeH2 blockers improve nocturnal gastric acid control in GERD
patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351–56
19.
‘Consumer reports Best Buy Drugs. Drugs
to Treat Heartburn and Stomach Acid Reflux: The Proton Pump Inhibitors’. Consumerreports.com
February 10, 2011 <http://www. consumerreports.org/health/resources/pdf/best-buy-drugs/PPIsUpdate-FINAL.pdf>
20.
Savarino V, Mario F.D, Scarpignato C.
Proton pump inhibitors in GORD An overview of their pharmacology and efficacy
and safety. Pharmacol Res. 2008; 26: 1-19
21.
Marchetti F, Gerarduzzi T, Ventura A.
Proton pump inhibitors in children: a review Digestive and Liver Disease. 2003;
35: 738–46
22.
Tauseef A,
David N.R, William M, et al.
Long-term Safety Concerns with Proton Pump Inhibitors The Am Journal of
Med. 2009; 122(10): 897-902
23.
Claudene J.G,
Beatriz K, Joseph S.R. Appropriate Proton Pump Inhibitor Use Among Older
Adults: A Retrospective Chart Review. Am J
Geriatr Pharmacother. 2008; 6: 249-54
24.
Ali RA, Egan LJ. Gastroesophageal reflux disease in
pregnancy. Best Pract Res Clin Gastroenterol. 2007;
21(5): 793–806
25.
Miner P, Katz O.P, Chen Y. et al. Gastric acid control with
Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole and Rabeprazole: A five
way crossover study. Am J Gastroenterol. 2003; 98: 2616-20
26.
Scarpignato C. New drugs to suppress acid
secretion: current and future developments. Drug Disc today:Ther strat. 2007;
4(3): 155-63
27.
Santarus, Inc. Data on file 2004.
28.
Small R. Advances in Proton Pump
Inhibitor Therapy: An Immediate-Release Formulation of Omeprazole. Pharmacy and
Therapeutics. 2005; 30(12): 698-715
29.
Wittbrodt E, Baum C, Peura D. Delayed
release dexlansoprazole in treatment of GERD and erosive esophagitis. Clin Exp
Gastroenterol. 2009; 2: 117-28
30.
Dexilant product monograph
31.
Morelli G, Chen H, Rossiter G. et al. An open-label, parallel,
multiple-dose study comparing the pharmacokinetics and gastric acid suppression
of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole
delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther. 2011;
33(7) : 845-54
32.
Hunt R.H, Armstrong D, Yaghoobi M. et al. Predictable prolonged suppression
of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment
Pharmacol Ther. 2008; 28: 187-99
33.
Zang W, Wu J, Atkinson S.
Pharmacokinetics, pharmacodynamics and safety evaluation of a single and
multiple 60 mg, 90 mg and 120 mg oral doses of modified release TAK-390
{TAK-390MR} and 30 mg oral doses of lansoprazole in healthy subjects.
Gantroenterology. 2007; 132: A-487
34.
Vakily M, Zhang W, Wu J, Atkinson S. et al. Pharmacokinetics and
pharmacodynamics of a known active PPI with novel Dual Delayed Release
technology, dexlansoprazole MR: a combined analysis of randomized controlled
clinical trials. Curr Med Res Opin. 2009; 25: 627-38